Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | PADI1 | Q9ULC6 | 1/20 | 0.34 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6921848 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2PIK3CDCHRM5CHRM3CYP2D6 | |
| Ammonia Solution, Strong SCHEMBL1308109 | 0.97 | SMN1; SMN2 (0.48) | SMN1; SMN2PIK3CDCHRM5CHRM3CYP2D6 | |
| Hydrochloric Acid SCHEMBL6619286 | 0.97 | SMN1; SMN2 (0.53) | SMN1; SMN2PIK3CDCHRM5CHRM3CYP2D6 | |
| Hydrochloric Acid SCHEMBL7515490 | 0.97 | SMN1; SMN2 (0.53) | SMN1; SMN2PIK3CDCHRM5CHRM3CYP2D6 | |
| Hydrochloric Acid SCHEMBL27682155 | 0.95 | SMN1; SMN2 (0.52) | SMN1; SMN2PIK3CDCHRM5CHRM3CYP2D6 | |
| SCHEMBL9829105 | 0.91 | CXCR4 (0.50) | SMN1; SMN2PIK3CDCHRM5CHRM3CXCR4 | |
| SCHEMBL9059950 | 0.85 | — | — | |
| SCHEMBL13850118 | 0.85 | CXCR4 (0.43) | SMN1; SMN2PIK3CDCHRM5CHRM3CYP2D6 | |
| SCHEMBL14145045 | 0.84 | SMN1; SMN2 (0.40) | SMN1; SMN2PIK3CDCHRM5CHRM3CYP2D6 | |
| Hydrochloric Acid SCHEMBL28025694 | 0.83 | SMN1; SMN2 (0.42) | SMN1; SMN2PIK3CDCHRM5CHRM3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 961 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | claimed |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | claimed |
| CN-113717201-B | (+/-) -Marinopyrole A derivative and preparation method and application thereof | 植恩生物技术股份有限公司 | 2022-12-16 | — | — | CN | claimed |
| CN-114516642-A | MOR molecular sieve, and preparation method and application thereof | 中国科学院大连化学物理研究所 | 2022-05-20 | — | — | CN | claimed |
| US-10689325-B2 | Process for the preparation of an antibody-rifamycin conjugate | GENENTECH, INC. (US) | 2020-06-23 | — | — | US | claimed |
| CN-108946762-B | Hierarchical porous EU-1 molecular sieve and preparation method thereof | 中触媒新材料股份有限公司 | 2020-02-14 | — | — | CN | claimed |
| US-20190270695-A1 | PROCESS FOR THE PREPARATION OF AN ANTIBODY-RIFAMYCIN CONJUGATE | GENENTECH, INC. (US) | 2019-09-05 | — | — | US | claimed |
| CN-108946762-A | A kind of multi-stage porous EU-1 molecular sieve and preparation method thereof | 中触媒新材料股份有限公司 | 2018-12-07 | — | — | CN | claimed |
| CN-108713020-A | The method for preparing antibody-rifamycin conjugate | 豪夫迈·罗氏有限公司 | 2018-10-26 | — | — | CN | claimed |
| US-20170252457-A1 | PROCESS FOR THE PREPARATION OF AN ANTIBODY-RIFAMYCIN CONJUGATE | GENENTECH, INC. (US) | 2017-09-07 | — | — | US | claimed |
| US-20040209892-A1 | Heterocyclic compounds and methods of use | U.S. PATENT OPERATIONS | 2004-10-21 | — | — | US | claimed |
| WO-2004039796-A1 | HETEROARYLOXY-SUBSTITUTED PHENYLAMINOPYRIMIDINES AS RHO-KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2004-05-13 | — | — | WO | claimed |
| US-6355635-B1 | IMIDAZOLEBENZENE, IMIDAZOLEPYRIDINE COMPOUNDS FOR TREATMENT OF OBESITY | PFIZER INC. | 2002-03-12 | — | — | US | claimed |
| US-20010039277-A1 | Compounds for the treatment of obesity | ELLIOTT RICHARD L (US) | 2001-11-08 | — | — | US | claimed |
| WO-2000066578-A1 | COMPOUNDS FOR THE TREATMENT OF OBESITY | PFIZER PRODUCTS INC. (US) | 2000-11-09 | — | — | WO | claimed |
| CN-1033163-C | Process for preparation of lifumycin of isobuty piperazine | NORTHEASTERN GENERAL PHARMACEU (CN) | 1996-10-30 | — | — | CN | claimed |
| EP-0328924-B1 | Thienotriazolodiazepine compounds and pharmaceutical uses thereof | YOSHITOMI PHARMACEUTICAL (JP) | 1996-08-21 | — | — | EP | claimed |
| CN-1025999-C | Imidazo [4,5-B] quinolinyloxyalkanoic acid amides with enhanced water solubility | BRISTOL MYERS SQUIBB CO (US) | 1994-09-28 | — | — | CN | claimed |
| CN-1063105-A | The preparation method of Rifin | NORTHEASTERN GENERAL PHARMACEU (CN) | 1992-07-29 | — | — | CN | claimed |
| CN-1051359-A | Improved imidazo [4, the 5-b] quinolinyloxyalkanoic acid amides of water-soluble degree | BRISTOL MYERS SQUIBB CO (US) | 1991-05-15 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | SMN1; SMN2 564/4885PIK3CD 3833/4885CHRM5 4105/4885 |
| US-20190270695-A1 | PROCESS FOR THE PREPARATION OF AN ANTIBODY-RIFAMYCIN CONJUGATE | FUCA2, MRPL21, FNTB | SMN1; SMN2 3414/4885PIK3CD 2624/4885CHRM5 1710/4885 |
| US-10689325-B2 | Process for the preparation of an antibody-rifamycin conjugate | FUCA2, MRPL21, FNTB | SMN1; SMN2 3414/4885PIK3CD 2624/4885CHRM5 1710/4885 |
| US-20040209892-A1 | Heterocyclic compounds and methods of use | VHL, NQO1, HPGDS | SMN1; SMN2 2240/4885PIK3CD 1302/4885CHRM5 3623/4885 |
| US-20010039277-A1 | Compounds for the treatment of obesity | NPY1R, NPY4R, NPY2R | SMN1; SMN2 3943/4885PIK3CD 2933/4885CHRM5 731/4885 |
| US-20170252457-A1 | PROCESS FOR THE PREPARATION OF AN ANTIBODY-RIFAMYCIN CONJUGATE | FUCA2, MRPL21, FNTB | SMN1; SMN2 3414/4885PIK3CD 2624/4885CHRM5 1710/4885 |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | HBZ, ZFX, WIZ | SMN1; SMN2 564/4885PIK3CD 3833/4885CHRM5 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.